These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

610 related items for PubMed ID: 25636908

  • 1. MiR-203 down-regulates Rap1A and suppresses cell proliferation, adhesion and invasion in prostate cancer.
    Xiang J, Bian C, Wang H, Huang S, Wu D.
    J Exp Clin Cancer Res; 2015 Jan 31; 34(1):8. PubMed ID: 25636908
    [Abstract] [Full Text] [Related]

  • 2. Long noncoding RNA CRNDE promotes proliferation, migration and invasion in prostate cancer through miR-101/Rap1A.
    Chen JH, Tong W, Pu XF, Wang JZ.
    Neoplasma; 2020 May 31; 67(3):584-594. PubMed ID: 32182086
    [Abstract] [Full Text] [Related]

  • 3. Role of miR-337-3p and its target Rap1A in modulating proliferation, invasion, migration and apoptosis of cervical cancer cells.
    Cao XM.
    Cancer Biomark; 2019 May 31; 24(3):257-267. PubMed ID: 30883336
    [Abstract] [Full Text] [Related]

  • 4. miR-195 Inhibits Tumor Progression by Targeting RPS6KB1 in Human Prostate Cancer.
    Cai C, Chen QB, Han ZD, Zhang YQ, He HC, Chen JH, Chen YR, Yang SB, Wu YD, Zeng YR, Qin GQ, Liang YX, Dai QS, Jiang FN, Wu SL, Zeng GH, Zhong WD, Wu CL.
    Clin Cancer Res; 2015 Nov 01; 21(21):4922-34. PubMed ID: 26080838
    [Abstract] [Full Text] [Related]

  • 5. MicroRNA-194 suppresses prostate cancer migration and invasion by downregulating human nuclear distribution protein.
    Kong Q, Chen XS, Tian T, Xia XY, Xu P.
    Oncol Rep; 2017 Feb 01; 37(2):803-812. PubMed ID: 27959429
    [Abstract] [Full Text] [Related]

  • 6. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
    Ling Z, Wang X, Tao T, Zhang L, Guan H, You Z, Lu K, Zhang G, Chen S, Wu J, Qian J, Liu H, Xu B, Chen M.
    J Exp Clin Cancer Res; 2017 Nov 15; 36(1):159. PubMed ID: 29141691
    [Abstract] [Full Text] [Related]

  • 7. Reciprocal regulation of PCGEM1 and miR-145 promote proliferation of LNCaP prostate cancer cells.
    He JH, Zhang JZ, Han ZP, Wang L, Lv YB, Li YG.
    J Exp Clin Cancer Res; 2014 Sep 10; 33(1):72. PubMed ID: 25200485
    [Abstract] [Full Text] [Related]

  • 8. The biological functions and mechanism of miR‑212 in prostate cancer proliferation, migration and invasion via targeting Engrailed-2.
    Zhou Y, Ji Z, Yan W, Zhou Z, Li H.
    Oncol Rep; 2017 Sep 10; 38(3):1411-1419. PubMed ID: 28713997
    [Abstract] [Full Text] [Related]

  • 9. miR-221-5p regulates proliferation and migration in human prostate cancer cells and reduces tumor growth in vivo.
    Kiener M, Chen L, Krebs M, Grosjean J, Klima I, Kalogirou C, Riedmiller H, Kneitz B, Thalmann GN, Snaar-Jagalska E, Spahn M, Kruithof-de Julio M, Zoni E.
    BMC Cancer; 2019 Jun 25; 19(1):627. PubMed ID: 31238903
    [Abstract] [Full Text] [Related]

  • 10. MicroRNA-132/212 Upregulation Inhibits TGF-β-Mediated Epithelial-Mesenchymal Transition of Prostate Cancer Cells by Targeting SOX4.
    Fu W, Tao T, Qi M, Wang L, Hu J, Li X, Xing N, Du R, Han B.
    Prostate; 2016 Dec 25; 76(16):1560-1570. PubMed ID: 27527117
    [Abstract] [Full Text] [Related]

  • 11. Loss of miR-449a-caused PrLZ overexpression promotes prostate cancer metastasis.
    Chen W, Liu Y, Chen H, Ning H, Ding K.
    Int J Oncol; 2017 Aug 25; 51(2):435-444. PubMed ID: 28627667
    [Abstract] [Full Text] [Related]

  • 12. CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer.
    Xie C, Jiang XH, Zhang JT, Sun TT, Dong JD, Sanders AJ, Diao RY, Wang Y, Fok KL, Tsang LL, Yu MK, Zhang XH, Chung YW, Ye L, Zhao MY, Guo JH, Xiao ZJ, Lan HY, Ng CF, Lau KM, Cai ZM, Jiang WG, Chan HC.
    Oncogene; 2013 May 02; 32(18):2282-91, 2291.e1-7. PubMed ID: 22797075
    [Abstract] [Full Text] [Related]

  • 13. Down-regulation of miR-605 promotes the proliferation and invasion of prostate cancer cells by up-regulating EN2.
    Zhou YJ, Yang HQ, Xia W, Cui L, Xu RF, Lu H, Xue Z, Zhang B, Tian ZN, Cao YJ, Xing ZY, Yin S, He XZ.
    Life Sci; 2017 Dec 01; 190():7-14. PubMed ID: 28943214
    [Abstract] [Full Text] [Related]

  • 14. Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancer.
    Chiyomaru T, Yamamura S, Fukuhara S, Hidaka H, Majid S, Saini S, Arora S, Deng G, Shahryari V, Chang I, Tanaka Y, Tabatabai ZL, Enokida H, Seki N, Nakagawa M, Dahiya R.
    PLoS One; 2013 Dec 01; 8(3):e58929. PubMed ID: 23554959
    [Abstract] [Full Text] [Related]

  • 15. miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions.
    Hagman Z, Larne O, Edsjö A, Bjartell A, Ehrnström RA, Ulmert D, Lilja H, Ceder Y.
    Int J Cancer; 2010 Dec 15; 127(12):2768-76. PubMed ID: 21351256
    [Abstract] [Full Text] [Related]

  • 16. miR-326 functions as a tumor suppressor in human prostatic carcinoma by targeting Mucin1.
    Liang X, Li Z, Men Q, Li Y, Li H, Chong T.
    Biomed Pharmacother; 2018 Dec 15; 108():574-583. PubMed ID: 30243091
    [Abstract] [Full Text] [Related]

  • 17. MiR-501-3p functions as a tumor suppressor in non-small cell lung cancer by downregulating RAP1A.
    Lu J, Zhou L, Wu B, Duan Y, Sun Y, Gu L, Xu D, Du C.
    Exp Cell Res; 2020 Feb 01; 387(1):111752. PubMed ID: 31805277
    [Abstract] [Full Text] [Related]

  • 18. miR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer.
    Tao J, Zhi X, Zhang X, Fu M, Huang H, Fan Y, Guan W, Zou C.
    J Exp Clin Cancer Res; 2015 Nov 14; 34():139. PubMed ID: 26576539
    [Abstract] [Full Text] [Related]

  • 19. miR-564 inhibited metastasis and proliferation of prostate cancer by targeting MLLT3.
    Meng FJ, Meng FM, Wu HX, Cao XF.
    Eur Rev Med Pharmacol Sci; 2017 Nov 14; 21(21):4828-4834. PubMed ID: 29164580
    [Abstract] [Full Text] [Related]

  • 20. The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2F5 and PFTK1.
    Li SM, Wu HL, Yu X, Tang K, Wang SG, Ye ZQ, Hu J.
    J Exp Clin Cancer Res; 2018 Sep 05; 37(1):219. PubMed ID: 30185212
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.